Shockwave Medical, part of Johnson & Johnson MedTech, has announced the full U.S. launch of its Shockwave E8 peripheral intravascular lithotripsy (IVL) catheter, following clearance by the Food and Drug Administration (FDA).
A company press release details that the Shockwave E8 catheter is designed to optimize the treatment of patients with calcified femoropopliteal and below-the-knee peripheral arterial disease (PAD), including patients with complex chronic limb-threatening ischemia (CLTI).
“Shockwave’s newest peripheral catheter offers significant improvements that will help physicians refine their treatment algorithm and better support challenging patients with heavily calcified disease,” said Venita Chandra, MD, vascular surgeon and clinical associate professor in the Division of Vascular Surgery at Stanford Health Care in Stanford, California. “The catheter’s ability to treat long lesions and its extended reach enable safe and effective treatment of some of our most difficult-to-treat patients, including those with CLTI, a complicated and severe disease state with a high mortality rate.”
